Louis M. Weiner - Publications

Affiliations: 
Tumor Biology Georgetown University, Washington, DC 
Area:
Cell Biology, Immunology, Molecular Biology

81 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Zhang YW, Nasto RE, Jablonski SA, Serebriiskii IG, Surana R, Murray J, Johnson M, Riggins RB, Clarke R, Golemis EA, Weiner LM. RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio-Protocol. 7. PMID 29250574 DOI: 10.21769/BioProtoc.2435  0.96
2017 Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunology, Immunotherapy : Cii. PMID 29043413 DOI: 10.1007/s00262-017-2077-9  0.48
2015 Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. PMID 26507197 DOI: 10.1007/s00280-015-2855-z  0.96
2015 Parren PW, Burton DR, Bradbury A, Huston JS, Carter PJ, Veldman T, Chester KA, Larrick JW, Alfenito MR, Scott JK, Weiner LM, Adams GP, Reichert JM. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA. Mabs. 7: 981-8. PMID 26421752 DOI: 10.1080/19420862.2015.1089707  0.96
2015 Weiner LM. Cancer immunology for the clinician. Clinical Advances in Hematology & Oncology : H&O. 13: 299-306. PMID 26352774  0.96
2015 Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ressom H, Petricoin E, Clarke R, ... ... Weiner LM, et al. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene. PMID 26165839 DOI: 10.1038/onc.2015.226  0.96
2015 Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell. 27: 489-501. PMID 25873172 DOI: 10.1016/j.ccell.2015.03.004  0.96
2015 von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 75: 1047-55. PMID 25791363 DOI: 10.1007/s00280-015-2705-z  0.96
2015 AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. Journal of Clinical Pharmacology. 55: S4-20. PMID 25707963 DOI: 10.1002/jcph.407  0.96
2014 Larrick JW, Parren P, Huston JS, Plückthun A, Bradbury A, Tomlinson IM, Chester KA, Burton DR, Adams GP, Weiner LM, Scott JK, Alfenito MR, Veldman T, Reichert JM. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014. Mabs. 6: 1115-23. PMID 25517297 DOI: 10.4161/19420862.2014.971627  0.96
2014 Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunology Research. 2: 1186-98. PMID 25300860 DOI: 10.1158/2326-6066.CIR-14-0083  0.96
2014 Surana R, Wang S, Xu W, Jablonski SA, Weiner LM. IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model. Cancer Immunology Research. 2: 1103-12. PMID 25204776 DOI: 10.1158/2326-6066.CIR-14-0103  0.96
2014 Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. PMID 25171298 DOI: 10.1097/COC.0000000000000118  0.96
2014 Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 123: 3016-26. PMID 24652987 DOI: 10.1182/blood-2013-10-533398  0.96
2014 Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clinical Colorectal Cancer. 13: 81-6. PMID 24512954 DOI: 10.1016/j.clcc.2013.12.005  0.96
2014 Shivapurkar N, Weiner LM, Marshall JL, Madhavan S, Deslattes Mays A, Juhl H, Wellstein A. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. Plos One. 9: e84686. PMID 24400111 DOI: 10.1371/journal.pone.0084686  0.96
2014 Kim SS, Rait A, Rubab F, Rao AK, Kiritsy MC, Pirollo KF, Wang S, Weiner LM, Chang EH. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 278-91. PMID 24113515 DOI: 10.1038/mt.2013.231  0.96
2013 Madhavan S, Gusev Y, Natarajan TG, Song L, Bhuvaneshwar K, Gauba R, Pandey A, Haddad BR, Goerlitz D, Cheema AK, Juhl H, Kallakury B, Marshall JL, Byers SW, Weiner LM. Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Frontiers in Genetics. 4: 236. PMID 24312117 DOI: 10.3389/fgene.2013.00236  0.96
2013 Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biotherapy & Radiopharmaceuticals. 28: 274-82. PMID 23611188 DOI: 10.1089/cbr.2012.1329  0.96
2013 Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, ... ... Weiner LM, et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discovery. 3: 96-111. PMID 23125191 DOI: 10.1158/2159-8290.CD-12-0031  0.96
2013 Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 581-9. PMID 23104982 DOI: 10.1096/fj.12-210377  0.96
2012 Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Molecular Cancer Therapeutics. 11: 2674-84. PMID 23075808 DOI: 10.1158/1535-7163.MCT-12-0692  0.96
2012 Marquardt J, Begent RH, Chester K, Huston JS, Bradbury A, Scott JK, Thorpe PE, Veldman T, Reichert JM, Weiner LM. IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA. Mabs. 4: 648-52. PMID 23007482 DOI: 10.4161/mabs.22221  0.96
2012 Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. The New England Journal of Medicine. 366: 1156-8. PMID 22435376 DOI: 10.1056/NEJMcibr1114526  0.96
2012 Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 148: 1081-4. PMID 22424219 DOI: 10.1016/j.cell.2012.02.034  0.96
2012 Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology. 22: 3-13. PMID 22245472 DOI: 10.1016/j.semcancer.2011.12.009  0.96
2012 Wang S, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology, Immunotherapy : Cii. 61: 49-61. PMID 21842208 DOI: 10.1007/s00262-011-1090-7  0.96
2011 Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso K, Carabet LA, Song L, Riggins RB, Dakshanamurthy S, Wang Y, Byers SW, Clarke R, ... Weiner LM, et al. G-DOC: a systems medicine platform for personalized oncology. Neoplasia (New York, N.Y.). 13: 771-83. PMID 21969811 DOI: 10.1593/neo.11806  0.96
2011 Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nature Reviews. Cancer. 11: 523-32. PMID 21677677 DOI: 10.1038/nrc3081  0.96
2011 Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Research. 71: 2250-9. PMID 21406401 DOI: 10.1158/0008-5472.CAN-10-2277  0.96
2011 Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. American Journal of Clinical Oncology. 34: 70-5. PMID 20458210 DOI: 10.1097/COC.0b013e3181d2734a  0.96
2010 Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, ... Weiner LM, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science Signaling. 3: ra67. PMID 20858866 DOI: 10.1126/scisignal.2001083  0.96
2010 Deeken JF, Weiner LM. Supportive treatments for oncology patients: not just icing on the cake. Annals of Internal Medicine. 153: 411-2. PMID 20855805 DOI: 10.7326/0003-4819-153-6-201009210-00010  0.96
2010 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews. Immunology. 10: 317-27. PMID 20414205 DOI: 10.1038/nri2744  0.96
2010 Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prevention Research (Philadelphia, Pa.). 3: 410-5. PMID 20332297 DOI: 10.1158/1940-6207.CAPR-10-0040  0.96
2009 Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5323-37. PMID 19723653 DOI: 10.1158/1078-0432.CCR-09-0737  0.96
2009 Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet (London, England). 373: 1033-40. PMID 19304016 DOI: 10.1016/S0140-6736(09)60251-8  0.96
2009 Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion On Therapeutic Targets. 13: 339-62. PMID 19236156 DOI: 10.1517/14712590902735795  0.96
2008 Urtishak S, Alpaugh RK, Weiner LM, Swaby RF. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. Biomarkers in Medicine. 2: 137-45. PMID 20477435 DOI: 10.2217/17520363.2.2.137  0.96
2008 Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG. Translational Research Working Group developmental pathway for immune response modifiers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5692-9. PMID 18794077 DOI: 10.1158/1078-0432.CCR-08-1266  0.96
2008 Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 37: 154-8. PMID 18665076 DOI: 10.1097/MPA.0b013e31816618ce  0.96
2008 Weiner LM. Cancer immunotherapy--the endgame begins. The New England Journal of Medicine. 358: 2664-5. PMID 18565858 DOI: 10.1056/NEJMp0803663  0.96
2008 Weiner LM. From the Guest Editor: Monoclonal antibodies have emerged as versatile and useful cancer therapeutics. Cancer Journal (Sudbury, Mass.). 14: 147-8. PMID 18536553 DOI: 10.1097/PPO.0b013e3181772280  0.96
2008 Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. Journal of Immunology (Baltimore, Md. : 1950). 180: 6392-401. PMID 18424763  0.96
2008 Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. American Journal of Clinical Oncology. 31: 1-5. PMID 18376220 DOI: 10.1097/COC.0b013e31805c142f  0.96
2008 Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 502-8. PMID 18223225 DOI: 10.1158/1078-0432.CCR-07-1509  0.96
2007 Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy. 6: 1691-9. PMID 18032930  0.96
2007 Heimann DM, Weiner LM. Monoclonal antibodies in therapy of solid tumors. Surgical Oncology Clinics of North America. 16: 775-92, viii. PMID 18022544 DOI: 10.1016/j.soc.2007.07.001  0.96
2007 Weiner LM. Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews. Cancer. 7: 701-6. PMID 17721434 DOI: 10.1038/nrc2209  0.96
2007 Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. Journal of Immunology (Baltimore, Md. : 1950). 179: 2815-23. PMID 17709495  0.96
2007 Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 577-90. PMID 17667521 DOI: 10.1097/CJI.0b013e318064e7b2  0.96
2007 Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. International Journal of Radiation Oncology, Biology, Physics. 69: 358-63. PMID 17532577 DOI: 10.1016/j.ijrobp.2007.03.053  0.96
2007 Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 455-67. PMID 17457220 DOI: 10.1097/CJI.0b013e31803bb421  0.96
2007 Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 109: 170-9. PMID 17154393 DOI: 10.1002/cncr.22402  0.96
2006 Weiner LM, Borghaei H. Targeted therapies in solid tumors: monoclonal antibodies and small molecules. Human Antibodies. 15: 103-11. PMID 17065741  0.96
2006 Movsas B, Diratzouian H, Hanlon A, Cooper H, Freedman G, Konski A, Sigurdson E, Hoffman J, Meropol NJ, Weiner LM, Coia L, Lanciano R, Stein J, Kister D, Eisenberg B. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. American Journal of Clinical Oncology. 29: 435-41. PMID 17023775 DOI: 10.1097/01.coc.0000227480.41414.f2  0.96
2006 Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, ... ... Weiner LM, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clinical Colorectal Cancer. 6: 125-32. PMID 16945168 DOI: 10.3816/CCC.2006.n.029  0.96
2006 Scallon BJ, Snyder LA, Anderson GM, Chen Q, Yan L, Weiner LM, Nakada MT. A review of antibody therapeutics and antibody-related technologies for oncology. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 351-64. PMID 16799330 DOI: 10.1097/01.cji.0000199196.97845.c3  0.96
2006 Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1599-605. PMID 16533787 DOI: 10.1158/1078-0432.CCR-05-2217  0.96
2006 Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Annals of Surgical Oncology. 13: 214-20. PMID 16418887 DOI: 10.1245/ASO.2006.01.001  0.96
2006 Weiner LM. Fully human therapeutic monoclonal antibodies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 1-9. PMID 16365595  0.96
2005 Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biotherapy & Radiopharmaceuticals. 20: 603-13. PMID 16398612 DOI: 10.1089/cbr.2005.20.603  0.96
2005 Snyder LC, Astsaturov I, Weiner LM. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clinical Colorectal Cancer. 5: S71-80. PMID 16336752 DOI: 10.3816/CCC.2005.s.010  0.96
2005 Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 23: 1147-57. PMID 16151408 DOI: 10.1038/nbt1137  0.96
2005 Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW, O'Hara SM. Global gene expression profiling of circulating tumor cells. Cancer Research. 65: 4993-7. PMID 15958538 DOI: 10.1158/0008-5472.CAN-04-4330  0.96
2005 Weiner LM, Carter P. Tunable antibodies. Nature Biotechnology. 23: 556-7. PMID 15877072 DOI: 10.1038/nbt0505-556  0.96
2005 Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 4: 351-60. PMID 15767544 DOI: 10.1158/1535-7163.MCT-04-0269  0.96
2004 Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. The Journal of Biological Chemistry. 279: 53907-14. PMID 15471859 DOI: 10.1074/jbc.M407888200  0.96
2004 Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Research. 64: 6200-6. PMID 15342405 DOI: 10.1158/0008-5472.CAN-03-2382  0.96
2004 Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2122-32. PMID 15169798 DOI: 10.1200/JCO.2004.08.083  0.96
2004 Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. International Journal of Radiation Oncology, Biology, Physics. 58: 984-90. PMID 14967460 DOI: 10.1016/j.ijrobp.2003.09.098  0.96
2004 Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 602-9. PMID 14966084 DOI: 10.1200/JCO.2004.12.034  0.96
2004 Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 53: 513-8. PMID 14760509 DOI: 10.1007/s00280-004-0764-7  0.96
2003 Goldberg M, Farma J, Lampert C, Colarusso P, Coia L, Frucht H, Goosenberg E, Beard M, Weiner LM. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report. The Journal of Thoracic and Cardiovascular Surgery. 126: 1168-73. PMID 14566264 DOI: 10.1016/S0022  0.96
2003 Cheng JD, Weiner LM. Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1590-5. PMID 12738710  0.96
2003 Weiner LM, Carter P. The rollercoaster ride to anti-cancer antibodies. Nature Biotechnology. 21: 510-1. PMID 12721576 DOI: 10.1038/nbt0503-510  0.96
2003 Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1301-6. PMID 12663718 DOI: 10.1200/JCO.2003.08.040  0.96
2003 von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annual Review of Medicine. 54: 343-69. PMID 12525678 DOI: 10.1146/annurev.med.54.101601.152442  0.96
2002 Lewis NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemotherapy and Pharmacology. 50: 257-65. PMID 12357298 DOI: 10.1007/s00280-002-0500-0  0.96
2002 Cheng JD, Dunbrack RL, Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Research. 62: 4767-72. PMID 12183436  0.96
2002 Weiner LM. Beyond neutrophil recovery: manipulation of the tumor microenvironment by GM-CSF to control cancer. Oncology (Williston Park, N.Y.). 16: 7-9. PMID 11829282  0.96
Show low-probability matches.